# Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

> **NCT07166094** · PHASE3 · RECRUITING · sponsor: **Genmab** · enrollment: 660 (estimated)

## Conditions studied

- Endometrial Cancer
- Recurrent or Progressive Endometrial Cancer

## Interventions

- **DRUG:** Rina-S
- **DRUG:** IC

## Key facts

- **NCT ID:** NCT07166094
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-28
- **Primary completion:** 2029-08
- **Final completion:** 2029-11
- **Target enrollment:** 660 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07166094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07166094, "Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07166094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*